跳至主要内容
临床试验/NCT00591994
NCT00591994已完成不适用

Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography

Faculdade de Medicina de Valenca2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2006年11月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100
试验地点
2
主要终点
THI - Tinnitus Handicap Inventory

研究概览

简要总结

Tinnitus is defined as the perception of sound in the absence of a external source. About 15 % of the population is believed to experience tinnitus and for about 20 % of them it may become a very serious problem. Total comprehension of tinnitus pathophysiology has not yet been achieved, but modern theories focus in brain hyperactivity following inner ear damage, with involvement of various neurotransmitters. Piribedil,a dopamin agonist, has been used to treat tinnitus, focusing in dopamine release, which is inhibitory. Electrophysiological methods,like acoustic otoemissions and electrocochleography may reveal the changes in peripherical and central auditory pathways and help to choose the specific patients who could benefit from piribedil treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • tinnitus for more than 6 months
  • THI > 38
  • no central acting drugs in the last 6 months
  • tympanogram type A-n

排除标准

  • vascular and muscular tinnitus
  • concomitant TMJ disorders
  • abnormal otoscopy
  • mixed and conductive hearing losses

结局指标

主要结局

THI - Tinnitus Handicap Inventory

时间窗: Months 3 and 6

次要结局

  • VAS - Visual Analog Scale(Months 3 and 6)

研究者

发起方
Faculdade de Medicina de Valenca
申办方类型
Other

研究点 (2)

Loading locations...

相似试验